Refer a Patient
Have a Patient with Generalized Myasthenia Gravis (gMG) Who May Be Interested in the ExpanD Study?
The ExpanD Study is a phase 2, randomized, double-blind, placebo-controlled, multicenter study. Approximately 70 participants will be enrolled in this study.
The investigational medication, ALXN2050, is a tablet taken twice a day orally that is being compared with a placebo for the treatment of gMG symptoms. Eventually, all participants enrolled in the ExpanD Study will receive the investigational medication.
The total duration of participation is approximately 125 weeks and consists of a screening period (up to 4 weeks), a primary evaluation period (8 weeks), an extended treatment period (26 weeks), and an open-label extension period (approximately 1.5 years). Final study assessments will be performed 30 days after a participant’s final study treatment dose.
The primary objective of the ExpanD Study is to assess the effectiveness of ALXN2050 compared with placebo in reducing symptoms of gMG in patients based on change in the myasthenia gravis activities of daily living (MG-ADL) score.
Key Inclusion Criteria
- At least 18 years of age
- Confirmed diagnosis of gMG
- MG-ADL score of at least 5
- On a stable dose of gMG medication, if applicable
(no requirement for concurrent gMG treatment)
- Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at screening
Key Exclusion Criteria
- History of seizure
- History of N. meningitidis infection
- History of thymectomy, thymomectomy, or any other thymic surgery within 12 months of screening
- Any untreated thymic malignancy, carcinoma, or thymoma
- Concomitant treatment with a complement inhibitor, rituximab, tacrolimus, or cyclosporine
There are additional eligibility requirements, which the study doctor can explain to interested individuals.